Vera Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VERA research report →
Range $43 – $125
Price Chart
About the company
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection.
- CEO
- Marshall Fordyce
- IPO
- 2021
- Employees
- 361
- HQ
- Brisbane, CA, US
Get TickerSpark's AI analysis on VERA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.11B
- P/E
- -5.02
- Fwd P/E
- 10.18
- PEG
- 0.12
- P/S
- 0.00
- P/B
- 5.18
- EV/EBITDA
- -5.48
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -84.13%
- ROIC
- -85.78%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-315,473,000
- Net Income
- $-299,615,000-96.9%
- EPS
- $-4.66-69.5%
- OCF Growth
- -79.0%
- FCF Growth
- -78.2%
- 52W High
- $56.05
- 52W Low
- $23.05
- 50D MA
- $32.97
- 200D MA
- $38.93
- Beta
- 0.95
- RSI (14)
- 35
- Avg Volume
- 2.28M
No earnings-call transcripts are available for VERA yet.
- Free Float
- 81.5%
- Shares Outstanding
- 71.78M
- Float Shares
- 58.51M
of shares held by institutions
234 13F filers
Buy/sell ratio 0.43. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 5.75M | ▲ 659.66K |
| Avoro Capital Advisors LLC | 5.72M | ▼ 165.00K |
| State Street Corp | 4.15M | ▲ 785.15K |
| Price T Rowe Associates Inc | 4.01M | ▼ 561.09K |
| Deep Track Capital, LP | 4.00M | ▼ 106.07K |
| Deerfield Management Company, L.P. (Series C) | 3.92M | ▲ 194.30K |
| Vanguard Group Inc | 3.57M | ▲ 379.75K |
| Kynam Capital Management, LP | 2.89M | ▼ 508.17K |
| Morgan Stanley | 2.80M | ▲ 2.43M |
| Sofinnova Investments, Inc. | 2.79M | 0 |
| Fmr LLC | 2.77M | ▲ 97.65K |
| Vanguard Capital Management LLC | 2.76M | ▲ 71.81K |
Held by 232 ETFs
Biggest fund positions in VERA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 15, 26 | Fordyce Marshall | other | 18,500 |
| Sep 15, 26 | Fordyce Marshall | other | 18,500 |
| Sep 15, 26 | Fordyce Marshall | sell | 18,500 |
| Sep 11, 26 | Young Joseph R | other | 5,000 |
| Sep 11, 26 | Young Joseph R | other | 5,000 |
| Sep 2, 26 | Fordyce Marshall | other | 18,500 |
| Sep 2, 26 | Fordyce Marshall | other | 18,500 |
| Sep 2, 26 | Fordyce Marshall | sell | 18,500 |
| Jul 7, 26 | Fordyce Marshall | other | 46,250 |
| Jul 7, 26 | Fordyce Marshall | other | 46,250 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VERA coverage
Recent articles, reports, and earnings notes.
No research on VERA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VERA report →Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Oct 2
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026
globenewswire.com · Oct 2
Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com · Sep 15
What's Going on With Vera Therapeutics Stock on Tuesday?
benzinga.com · Sep 15
Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results
barrons.com · Sep 15
Why is Vera Therapeutics stock reversing its premarket gains?
invezz.com · Sep 15
Vera Stock Slides Despite Positive Phase 3 Results
schaeffersresearch.com · Sep 15
Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
globenewswire.com · Sep 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.